CSIMarket


Panbela Therapeutics Inc   (PBLA)
Other Ticker:  
 


 

Panbela Therapeutics Inc

PBLA's Financial Statements and Analysis



Panbela Therapeutics Inc narrowed first quarter of 2024 net loss per share of $-2.28 compare to net loss per share of $-13.00 recorded in the same quarter a year ago and improved compare to net loss per share of $-176.90 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -2.28 $  0 Mill
$+10.72     Unch.    



Panbela Therapeutics Inc 's Revenue fell by 0 % in first quarter of 2024 (Mar 31 2024) year on year, to $0 million and declined by sequentially.


Panbela Therapeutics Inc is

More on PBLA's Income Statement



Panbela Therapeutics Inc in the first quarter of 2024 recorded net loss of $-7.120 million, an increase from net loss of $-5.113 million in I. Quarter a year ago.

Sequentially net loss advanced

More on PBLA's Growth

Panbela Therapeutics Inc Inventories
In Mar 31 2024 company's net cash and cash equivalents decreased by $-2 million


Panbela Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Panbela Therapeutics Inc payed $ -7.96 cash per share, on a free-cash flow basis .


Tangible Book value grew to $ -1.02 per share from $ -59.01.

Company issued 3.05 million shares or 3,816.36 % in Mar 31 2024.


More on PBLA's Dividends

 Market Capitalization (Millions) 1
 Shares Outstanding (Millions) 3
 Total Debt (Millions $) 3
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Panbela Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Panbela Therapeutics Inc had negative $ -7.96 cash flow per share, on a free-cash flow basis .


Tangible Book value grew to $ -1.02 per share from $ -59.01.

Company issued 3.05 million shares or 3,816.36 % in Mar 31 2024.


More on PBLA's Balance Sheets

 Market Capitalization (Millions) 1
 Shares Outstanding (Millions) 3
 Total Debt (Millions $) 3
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Panbela Therapeutics Inc Earnings

Headline: Panbela Therapeutics Inc Reports Growth and Achievements in Cancer Treatment Innovation, Despite Decrease in Financial Results for Q1 2024

Panbela Therapeutics Inc, a clinical stage company specializing in disruptive therapeutics for urgent unmet medical needs, recently provided a business update and reported its financial results for the quarter and full year ending December 31, 2023. The company also announced significant advancements and achievements in the field of cancer treatment.
One of the notable developments for Panbela Therapeutics is the issuance of a new patent in the United States and Canada for a fixed dose combination of Eflornithine and Sulindac. This combination therapy, developed in collaboration with leading pharmaceutical company Sanofi, represents a significant step forward in the fight against cancer. The new patent u...

Panbela Therapeutics Inc. Reports Operating Loss in Q4 2023

Panbela Therapeutics, Inc. (NASDAQ: PBLA) recen...

Panbela Therapeutics Inc Struggles Amidst Earnings Season, Discloses Operating Shortfall of $-7.846 Million in Q3 2023

Panbela Therapeutics Inc Faces Challenges as Earnings Season Resumes
As the July to September 30, 2023 reporting season resumes, many entities in the Major Pharmaceutical Preparations sector have disclosed their respective earnings. One such entity facing challenges is Panbela Therapeutics Inc (PBLA) which recently issued an operating shortfall of $-7.846 million for the third quarter of the 2023 earnings season.
While the company has not declared its revenue for this period, it is important to establish a frame of reference by analyzing its corporate efforts in the third quarter of 2022. During that time, Panbela Therapeutics Inc reported an operating shortfall of $-3.623 million. This information h...

Panbela Therapeutics Inc Delivers Impressive Q2 2023 Financial Results, Signaling a Turnaround in Performance



Panbela Therapeutics Inc, a prominent player in the Healthcare sector, has recently announced its impressive financial results for the April to June 2023 reporting cycle. The company has exhibited a notable decrease in operating losses compared to the previous year, sparking optimism among analysts. This article aims to interpret the financial results and assess their potential impact on Panbela Therapeutics Inc's future prospects.
1. Operating Shortfall Improvement:
During the April to June 2023 reporting cycle, Panbela Therapeutics Inc reported an operating shortfall of $-5.877 million, a significant improvement from the previous year's corresponding quarter, which recorded a shortfall of...

Panbela Therapeutics Inc's Surging Working Expenditures Spark Concerns in Q1 of 2023

Panbela Therapeutics Inc. is a pharmaceutical company that specializes in the development of oncology therapies. The company's goal is to create innovative treatments that can help patients with various forms of cancer. While Panbela Therapeutics has gained considerable attention for its ground-breaking research and development, its recent financial reports have come under the scrutiny of industry analysts.
The first quarter of 2023 financial reporting period has been marked by a significant operating loss of $-4.86 million. Moreover, the company has not specified any revenue for the respective January to March 31 2023 financial reporting period. This has raised eyebrows among analysts who are now questi...


Date modified: 2024-05-16T13:41:04+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com